India is the world’s third-largest pharmaceutical producer by volume and the largest supplier of generic medicines globally. That scale is also a vulnerability. According to the World Health Organization (WHO), approximately 1 in 10 medical products in low- and middle-income countries is substandard or falsified — a category that includes outright counterfeits, degraded medicines, and products with incorrect dosage or labelling (WHO Fact Sheet, 2023).
For Indian pharma companies, this is not an abstract global statistic. Fake versions of common generics and essential medicines circulate in both domestic and export markets. Regulatory bodies in the US and EU have issued import alerts and market withdrawals against Indian manufacturers. The Indian government has been tightening its traceability and serialization requirements progressively, and 2026 brings renewed urgency for compliance teams that have deferred action.
If you are a regulatory, compliance, or supply chain head at an Indian pharmaceutical company, this post covers what you need to know about CDSCO requirements, the serialization landscape, the obligations of exporting to the US or EU, and what a functional traceability system actually looks like in practice.
What Is CDSCO and What Role Does It Play in Drug Traceability?
The Central Drugs Standard Control Organisation (CDSCO) is India’s national regulatory authority for pharmaceuticals and medical devices, operating under the Ministry of Health and Family Welfare. CDSCO is the Indian equivalent of the US FDA or the European Medicines Agency. It is responsible for approving drugs, setting manufacturing standards, and regulating the import and export of pharmaceutical products.
On traceability, CDSCO’s role is multi-layered. It sets the requirements for labelling and serialization of scheduled drugs. It coordinates with state drug authorities on enforcement at the distribution level. It also interfaces with international regulatory bodies when Indian exports face scrutiny abroad.
CDSCO operates through the Drugs and Cosmetics Act, 1940, and the accompanying rules. Amendments and notifications under this Act establish traceability requirements for specific drug categories, and these have been updated repeatedly over the past decade as technology has advanced and the counterfeiting problem has become more documented.
CDSCO also administers the Central Drugs Laboratory system and issues import alerts for manufacturing units that fail inspections. Understanding CDSCO’s role matters because traceability compliance is not a one-time certification. It is an ongoing operational requirement that your manufacturing and supply chain functions need to maintain continuously.
Current Traceability Requirements for Indian Pharma Companies
Traceability requirements for Indian pharmaceutical companies are not uniform. They vary based on the drug schedule, the destination market (domestic or export), and whether the product is manufactured under a loan licence, a contract manufacturing arrangement, or at a company-owned facility.
For domestic distribution, the mandatory requirements under the Drugs and Cosmetics Rules include labelling with batch number, manufacturing date, expiry date, and manufacturer details. For scheduled drugs (particularly Schedule H, H1, and X, which cover antibiotics, narcotics, and psychotropics), additional documentation and record-keeping requirements apply.
The Ministry of Health has also issued notifications requiring barcode labelling on pharmaceutical products. The 2011 notification under Rule 96 of the Drugs and Cosmetics Rules required barcodes on certain categories of drugs, though implementation timelines were extended multiple times. Subsequent notifications have progressively expanded the scope of serialization requirements.
It is important to be accurate here: mandatory serialization at the unit-level (individual pack) is not uniformly enforced across all domestic drug categories as of 2026. However, the direction of regulatory movement is clearly toward full serialization, and companies that have not yet built this capability face both compliance risk and operational disruption when requirements tighten further.
For export-focused manufacturers, the requirements are significantly stricter and are largely driven by the regulations of the destination market rather than CDSCO alone.
The Barcode and Serialization Mandate: Where India Stands
India’s barcode and serialization journey has been incremental. The initial 2011 mandate covered a specific list of drugs and required 2D barcodes at the secondary packaging level (the carton), encoding batch number, manufacturing date, expiry date, and MRP. This requirement is in force.
Unit-level serialization, meaning a unique identifier on each individual pack that enables granular track-and-trace through the supply chain, has been discussed and piloted but not yet universally mandated for the domestic market across all drug categories. The government has been piloting serialization programs, particularly in the context of the eVIN (Electronic Vaccine Intelligence Network) and in schemes covering essential medicines and anti-TB drugs.
The practical implication for compliance teams is this: if your products are only sold domestically and do not fall under a specific scheduled category with explicit serialization requirements, you may be operating within the current legal minimum. But “current legal minimum” is a moving target, and the infrastructure investment required to move to full serialization is significant enough that companies that delay are building a larger future problem.
More importantly, if your products are exported to the US or EU, the serialization requirements are already strict and fully enforced.
DSCSA and EU FMD: What Indian Pharma Exporters Must Comply With
If your company exports to the United States or the European Union, your traceability obligations are determined by those markets’ laws, not just CDSCO.
DSCSA (Drug Supply Chain Security Act, United States): The DSCSA, enforced by the US FDA, requires unit-level serialization for all prescription drugs sold in the US market. Every pack must carry a unique Product Identifier containing the National Drug Code, serial number, lot number, and expiration date encoded in a 2D barcode (GS1 DataMatrix or equivalent). The DSCSA also requires interoperable electronic track-and-trace systems that allow the FDA and trading partners to trace a product through the entire supply chain. Full interoperability requirements came into effect in 2023. Indian manufacturers exporting to the US must comply or face import detention and alert-listing.
EU Falsified Medicines Directive (FMD): The EU FMD (Directive 2011/62/EU and Delegated Regulation 2016/161) requires unique identifiers and tamper-evident features on all prescription medicines sold in the European Economic Area. The unique identifier must be encoded in a 2D barcode and must be verified by authorised dispensers at the point of dispensing. Indian manufacturers exporting to EU markets must serialise their packs according to GS1 standards and connect to the European Medicines Verification System (EMVS).
Both DSCSA and EU FMD require manufacturer-level compliance. If your export lines are not serialised and your data is not flowing into the relevant verification systems, your products are not legally distributable in those markets.
What Happens When Pharma Companies Do Not Comply
The consequences of non-compliance are not hypothetical. Indian pharmaceutical manufacturers have faced significant enforcement actions in recent years, and the pattern is well-documented.
At the US FDA level, non-compliance with cGMP (current Good Manufacturing Practice) and traceability requirements can result in a Warning Letter, which becomes public record and signals to US buyers that the facility is at risk. A more severe outcome is an Import Alert, which gives the FDA authority to detain all products from that facility at the US border without individual examination. An Import Alert effectively shuts off a manufacturer’s access to the US market until the underlying issues are resolved and a re-inspection passes.
In the EU, products that cannot be verified against the EMVS must be quarantined or destroyed by the dispenser. A pattern of verification failures can trigger regulatory investigation and market withdrawal.
For domestic India, the consequences are primarily at the state drug authority level: manufacturing licence suspension, seizure of stock, and reputational damage from press coverage of enforcement actions. India’s drug regulatory enforcement has been more variable historically, but the direction is toward stricter enforcement as traceability infrastructure improves.
Beyond legal consequences, the commercial damage is significant. A manufacturing facility on Import Alert status loses its US business entirely until cleared. Rebuilding that market position after an alert can take years.
The Five Components of a Pharma Traceability System
A functional pharmaceutical traceability system is not a single technology. It is a set of five interconnected capabilities that need to work together.
- Serialization: Assigning a unique identifier to each product unit (and secondary/tertiary packaging). This is the foundation. Without unit-level unique identifiers, nothing else in the system works. The identifier is typically encoded in a 2D barcode per GS1 standards.
- Aggregation: Creating and maintaining a verified relationship between individual units and the cases or pallets they ship in. Aggregation enables efficient scanning at logistics nodes without scanning every individual pack. It also enables lot-level recall without unit-level scanning at distribution points.
- Track and Trace: Recording the movement of product through each node in the supply chain, from manufacturer to distributor to wholesaler to dispenser. This creates the chain of custody that regulators and trading partners can query when questions arise about product legitimacy.
- Verification: The ability for authorised parties (dispensers, inspectors, consumers) to verify that a specific product unit is genuine and has not been flagged as suspect. Verification is the consumer-facing and enforcement-facing function of the system.
- Recall Management: The ability to identify precisely which units or lots are affected by a safety issue, where they are in the supply chain, and initiate a targeted withdrawal. A functioning track-and-trace system transforms a recall from a broad, expensive market withdrawal into a targeted operation.
Companies that deploy serialization alone, without the aggregation, track-and-trace, and recall management layers, have the foundation but not a complete system. Regulators are increasingly evaluating the whole stack, not just the barcode on the pack.
How Blockchain Improves Pharma Traceability Beyond Basic Serialization
Serialization creates a unique identifier. Track-and-trace records movement. But both of these can be manipulated if the underlying data system is centralised and controlled by a single actor with an interest in the outcome.
Blockchain adds a property that centralised databases cannot provide: immutable, distributed record-keeping. When a product’s chain of custody is recorded on a blockchain, each transaction is cryptographically linked to the previous one. No single party, including the manufacturer, the distributor, or the technology vendor, can alter a historical record without that alteration being visible to all participants in the network.
For pharmaceutical traceability, this has practical value in several scenarios. Disputed custody claims (a distributor claims they never received a shipment that later shows up as counterfeit) can be resolved with reference to an immutable record. Regulatory audits can be conducted against a tamper-evident data set. And in a recall scenario, the integrity of the track-and-trace data is not in question because it cannot have been altered after the fact.
Blockchain-based traceability does not replace serialization or GS1-compliant barcoding. It adds a trust layer on top of the existing data, and it enables multi-party supply chain networks (where manufacturers, CMOs, distributors, and dispensers are independent entities) to share data without any single party controlling the historical record.
How Origin Supports CDSCO-Compliant Pharma Traceability
Acviss Origin is a blockchain-based supply chain traceability platform built for manufacturers operating in regulated industries. For pharmaceutical companies, Origin provides the serialization, aggregation, track-and-trace, and recall management capabilities that make up a complete traceability system, on a blockchain backbone that satisfies the immutability and auditability requirements of regulatory scrutiny.
Origin integrates with SAP and Microsoft Dynamics, which means it works alongside the manufacturing and ERP systems that most mid-to-large pharma companies already run. The integration avoids creating a parallel data silo: production orders, batch records, and dispatch data flow between your existing systems and the traceability layer without manual re-entry.
For Indian pharma exporters specifically, Origin’s serialization output is compatible with GS1 standards required for DSCSA and EU FMD compliance. The platform also includes geofencing capabilities, which allow your supply chain team to define authorised distribution territories and receive alerts when product is scanned outside those territories, a key tool for identifying grey market diversion and unauthorised distribution that can undermine export compliance.
Acviss works with companies in regulated industries, including Corteva Agriscience and ITC, and the platform is designed for deployment in environments where regulatory documentation and audit trails are part of the standard operating requirement. If you are evaluating a traceability platform against CDSCO and export market requirements, Origin is designed to meet that brief from day one of deployment.
Implementation Timeline: What to Expect When Deploying a Traceability Solution
Realistic implementation planning prevents the most common project failures. Here is what a typical pharma traceability deployment involves, and roughly how long each stage takes.
Months 1-2: Assessment and design. Current state mapping of your packaging lines, ERP configuration, and supply chain network. Definition of scope (which products, which markets, which supply chain tiers). Selection of serialization standards and barcode format. GS1 company prefix registration if not already in place.
Months 2-4: Infrastructure and integration. Serialization hardware installation or configuration on packaging lines (camera systems, label printing, rejection mechanisms). ERP integration development and testing. Platform configuration for your product master data, SKUs, and supply chain network.
Months 4-6: Pilot and validation. Live production run on a limited line with full data capture. Internal validation of serial number generation, aggregation accuracy, and data flow. Regulatory documentation for any required submissions.
Months 6-12: Rollout and optimisation. Expansion to additional lines and SKUs. Trading partner onboarding (distributors, wholesalers, export partners). Alert threshold configuration and recall drill testing.
Companies that try to compress this timeline significantly typically encounter data quality issues that create compliance risk. The goal of a phased approach is not conservatism. It is ensuring that the system you deploy actually works in a live production environment before you depend on it for regulatory compliance.
FAQ
What is the penalty for non-compliance with CDSCO drug traceability requirements?
Penalties under the Drugs and Cosmetics Act can include product seizure, manufacturing licence suspension, and prosecution of responsible persons. The severity depends on whether the violation involves substandard drugs, misbranded drugs, or specific scheduled substance regulations. For export markets, the consequence is typically an Import Alert (US) or market exclusion (EU), which are commercially more severe than domestic penalties for most large manufacturers.
Does Origin meet CDSCO requirements?
Origin provides the serialization, track-and-trace, and recall management capabilities required under CDSCO regulations for drug traceability, including output compliant with GS1 barcode standards referenced in Indian drug labelling requirements. For a specific assessment of how Origin maps to the current requirements applicable to your drug categories and markets, the Acviss team will walk through this with you during the onboarding evaluation. Requirements vary by drug schedule and destination market, so a generic yes/no answer is less useful than a mapping exercise against your specific product portfolio.
How long does deployment take?
For a single manufacturing line with existing ERP infrastructure, expect 4-6 months to a validated live state. Full rollout across multiple lines and product families typically runs 9-12 months. Companies starting from a low baseline of digital infrastructure (minimal ERP, no existing serialization hardware) should plan for the longer end of these ranges.
Can Origin integrate with our existing packaging lines?
Origin integrates with standard packaging line configurations and works with existing label printing and inspection systems from major vendors. The integration approach depends on your current line equipment, and the Acviss implementation team will assess this during the design phase. The platform is not restricted to specific hardware vendors, which avoids forcing a hardware replacement as a condition of deployment.
Talk to Our Pharma Traceability Team
CDSCO compliance, DSCSA, EU FMD, and the operational demands of running a serialized supply chain are a significant undertaking. The companies that manage it well start with a clear picture of where they stand against current requirements and a realistic plan for closing gaps.
Talk to our pharma traceability team about CDSCO-ready deployment. We will assess your current state, map your regulatory requirements, and give you a clear picture of what deployment looks like for your specific situation.
